Prolocor, Inc. Introduces a Breakthrough in Thrombosis Risk Diagnosis

On February 20, 2024, Prolocor, Inc., a health startup, announced the acceptance of its abstract by the American College of Cardiology (ACC) for its 2024 scientific session in Atlanta. The abstract, titled "ASSOCIATION BETWEEN PROGNOSTIC IMPLICATIONS OF PLATELET FcγRIIa (PFCG) AND TREATMENT STRATEGY FOR MYOCARDIAL INFARCTION," highlights the development of an innovative precision diagnostic test targeting thromboses through the quantification of FcγRIIa on platelets.

David J. Schneider, MD, FACC FAHA, co-founder and Chief Scientific Officer, along with Pete DiBattiste, MD, FACC, FAHA, co-founder and CEO of Prolocor, expressed their enthusiasm for these promising results and their significance in developing individualized treatment strategies for patients. This research aims to meet critical patient care needs and introduce significant innovations in the field of cardiology.

Prolocor, founded by experts in thrombosis and cardiovascular diseases, bases its strategy on leveraging FcγRIIa and aims to revolutionize the diagnosis of thrombosis risks. Future prospects seem promising despite warnings regarding forward-looking statements and the inherent challenges of developing innovative medical solutions.